BioSpace News Archive

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, announced a poster presentation at The Liver Meeting® 2020 hosted by the American Association for the Study of Liver Diseases to be held virtually November 13 – 16, 2020.

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , will present a poster this week at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting . The conference will be held online as a virtual event. Cygnal’s poster will discuss research on t

New Data From ARTISTRY-1 Trial Provide Additional Evidence of Therapeutic Potential of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in Multiple Tumor Types

StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells,

HUYA Bioscience International (HUYABIOTM), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the presentation of results from an ongoing Phase II study evaluating the efficacy and safety of HBI-8000 in combination with nivolumab in patients with advanced metastatic melanoma

OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020) taking place virtually November 9 to 14

Seagen Inc. (Nasdaq:SGEN) today announced the presentation of immuno-oncology data from its broad pipeline of therapies at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting 2020, taking place virtually November 9-14, 2020.

Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D

Positive interim analysis data from the TOPAZ Phase 2 trial demonstrated proof-of-concept for apitegromab (SRK-015) in patients with Type 2 and Type 3 Spinal Muscular Atrophy

Ikena Oncology, Inc. (“Ikena”), a clinical-stage, biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced that a poster presentation will take place at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting, taking place virtually November 9-14, 2020